Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

HK Type 4 license through Ballingal Investment Advisors Ltd. 

I'm a highly experienced sell-side analyst with in excess of 22 years of covering Asia Pacific equities, the past 19 years immersed in event strategies encompassing M&A risk arbitrage, directional long/short, stub trades and restructuring.  

My background also includes accountancy (liquidation/bankruptcy/receivership) earlier in my career and as a chief financial officer of a global commodity company based in the US and Mexico.

Pan-Asia Catalysts/Events

Mayne Pharma (MYX AU): Firm Support From Cosette Would Be Welcome About Now

Mayne Pharma (MYX AU): Scheme Booklet Dispatch Lends More Than A Veneer Of Support

Quiddity Advisors

Event-Driven

<ul>
<li>As widely speculated, Cosette <a href="https://announcements.asx.com.au/asxpdf/20250521/pdf/06jyjz3t1px3s2.pdf" target="_blank" rel="noopener">asserted</a> to <strong><a href="https://www.smartkarma.com/entities/mayne-pharma-group-ltd" target="_blank" data-smartkarma-citation="entities:757:1" rel="noopener">Mayne Pharma (MYX AU)</a></strong> on the 17th May a Material Adverse Change (MAC) has occurred.</li>
<li>Mayne disagrees, and views the pre-requisites for a MAC, as defined in the SID, have not been established. </li>
<li>What now? The Scheme is not terminated. Both parties remain in consultation. If those talks are not satisfactory (say, a price reduction [my guess]), Cosette said it will walk. </li>
</ul>


As widely speculated, Cosette asserted to Mayne Pharma (MYX AU) on the 17th May a Material Adverse Change (MAC) has occurred.
Mayne disagrees, and views the pre-requisites for a MAC, as defined in the SID, have not been established. 
What now? The Scheme is not terminated. Both parties remain in consultation. If those talks are not satisfactory (say, a price reduction [my guess]), Cosette said it will walk. 


Mayne Pharma

Mayne Disagrees With Cosette On MAC